The protozoan parasite Toxoplasma gondii is the causative agent of one of the most widespread parasitic infections of man and is a leading cause of congenital neurological birth defects and the third most common cause of food-borne deaths in the United States. Despite this, to date no drugs are available that provide a fully effective treatment. Recently, the antibacterial agent triclosan was shown to inhibit the fatty-acid biosynthesis pathway in T. gondii and to interact with the enoyl reductase (ENR). In order to analyse the potential of triclosan as a lead compound targeting T. gondii ENR and to explore unique features of the apicomplexan enzyme that could be exploited in future drug development, structural studies have been initiated o...
Toxoplasma gondii is an obligate intracellular parasite that has infected nearly 60 million individu...
To eliminate apicomplexan parasites, inhibitory compounds must cross host cell, parasitophorous vacu...
The use of natural products for treating protozoan infections can be traced back to Rome in 1631, wh...
The protozoan parasite Toxoplasma gondii is the causative agent of one of the most widespread parasi...
Recent studies have demonstrated that submicromolar concentrations of the biocide triclosan arrest t...
Enoyl acyl carrier protein reductase enzyme (ENR) catalyses one of the two reductive steps in fatty ...
Toxoplasmosis causes significant morbidity and mortality, and yet available medicines are limited by...
Recent studies have demonstrated that submicromolar concentrations of the biocide triclosan arrest t...
Toxoplasmosis causes significant morbidity and mortality, and yet available medicines are limited by...
Triclosan is a potent inhibitor of Toxoplasma gondii enoyl reductase (TgENR), which is an essential ...
Through our focused effort to discover new and effective agents against toxoplasmosis, a structure-b...
Many microbial pathogens rely on a type II fatty acid synthesis (FASII) pathway that is distinct fro...
Toxoplasma gondii, an Apicomplexan parasite, causes significant morbidity and mortality, including s...
Fab I, enoyl acyl carrier protein reductase (ENR), is an enzyme used in fatty acid synthesis. It is ...
AbstractThe enoyl acyl-carrier protein reductase (ENR) enzyme of the apicomplexan parasite family ha...
Toxoplasma gondii is an obligate intracellular parasite that has infected nearly 60 million individu...
To eliminate apicomplexan parasites, inhibitory compounds must cross host cell, parasitophorous vacu...
The use of natural products for treating protozoan infections can be traced back to Rome in 1631, wh...
The protozoan parasite Toxoplasma gondii is the causative agent of one of the most widespread parasi...
Recent studies have demonstrated that submicromolar concentrations of the biocide triclosan arrest t...
Enoyl acyl carrier protein reductase enzyme (ENR) catalyses one of the two reductive steps in fatty ...
Toxoplasmosis causes significant morbidity and mortality, and yet available medicines are limited by...
Recent studies have demonstrated that submicromolar concentrations of the biocide triclosan arrest t...
Toxoplasmosis causes significant morbidity and mortality, and yet available medicines are limited by...
Triclosan is a potent inhibitor of Toxoplasma gondii enoyl reductase (TgENR), which is an essential ...
Through our focused effort to discover new and effective agents against toxoplasmosis, a structure-b...
Many microbial pathogens rely on a type II fatty acid synthesis (FASII) pathway that is distinct fro...
Toxoplasma gondii, an Apicomplexan parasite, causes significant morbidity and mortality, including s...
Fab I, enoyl acyl carrier protein reductase (ENR), is an enzyme used in fatty acid synthesis. It is ...
AbstractThe enoyl acyl-carrier protein reductase (ENR) enzyme of the apicomplexan parasite family ha...
Toxoplasma gondii is an obligate intracellular parasite that has infected nearly 60 million individu...
To eliminate apicomplexan parasites, inhibitory compounds must cross host cell, parasitophorous vacu...
The use of natural products for treating protozoan infections can be traced back to Rome in 1631, wh...